

- 18 -

Claims

1. A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an LHRH analogue.

2. A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and a bisphosphonate.

3. A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, an LHRH analogue and a bisphosphonate.

4. A combination according to claims 1 or 3 wherein the LHRH analogue is an LHRH agonist.

5. A combination according to claim 4 wherein the LHRH agonist is selected from leuporelin, buserelin, triptorelin and goserelin.

6. A combination according to claims 4 or 5 wherein the LHRH agonist is goserelin.

7. A combination according to claims 1 or 3 wherein the LHRH analogue is an LHRH antagonist.

8. A combination according to claim 7 wherein the LHRH antagonist is selected from antide, abarelix, antarelix, cetorelix, azaline or ganirelix.

9. A combination according to claims 2 - 8 wherein the bisphosphonate is selected from tiludronic acid, ibandronic acid, incadronic acid, risedronic acid, zoledronic acid, clodronic acid, neridronic acid, pamidronic acid, alendronic acid, minodronic acid, olpadronic acid, TRK 530, CGP 47072, calcium clodronate or EB 1053.

- 19 -

10. A combination as claimed in any one of claims 1-9 for use as a medicament.

11. A pharmaceutical composition as claimed in any one of claims 1-9 in association with a pharmaceutically acceptable diluent or carrier.

5

12. A method of treating cancer, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a combination as claimed in any one of claims 1-9.

10 13. A pharmaceutical composition which comprises a combination as claimed in any one of claims 1-9 in association with a pharmaceutically acceptable diluent or carrier for use in the treatment of cancer.

15 14. The use of a combination as claimed in any one of claims 1-9 in the manufacture of a medicament for use in the treatment of cancer, in a warm-blooded animal, such as man.